The pharmaceutical revolution surrounding GLP-1 receptor agonist medications — semaglutide (marketed as Ozempic and Wegovy), tirzepatide (Mounjaro), and their successors — has fundamentally altered the weight management conversation. But as the supplement and functional food industries race to position products within this new paradigm, an unexpected contender has emerged from centuries of traditional use: yerba mate. Reporting by NutraIngredients and research covered by the Huberman Lab podcast have brought renewed attention to evidence that Ilex paraguariensis naturally stimulates the release of GLP-1, the same incretin hormone targeted by the blockbuster pharmaceutical class.
What GLP-1 Does — and Why It Matters
Glucagon-like peptide-1 (GLP-1) is a hormone secreted by intestinal L-cells in response to food intake. Its physiological effects include stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system signaling. The net result is reduced appetite and improved glycemic control — effects that have made GLP-1 receptor agonist drugs the most commercially successful new pharmaceutical class in a generation, with global sales projected to exceed $100 billion annually by the end of the decade.
The critical distinction is dose: pharmaceutical GLP-1 agonists deliver sustained supraphysiological receptor activation, producing dramatic weight loss of 15-20% of body weight in clinical trials. Natural GLP-1 stimulators — including yerba mate — operate at a fundamentally different order of magnitude, producing modest increases in endogenous GLP-1 secretion that may support appetite regulation without the gastrointestinal side effects associated with pharmacological doses.
The Yerba Mate–GLP-1 Connection
Research has demonstrated that yerba mate consumption increases circulating GLP-1 levels through mechanisms that appear to involve the interaction of chlorogenic acid, caffeine, and saponins with intestinal L-cell receptors. The effect has been documented in both animal models and limited human observational studies, with yerba mate consumers showing measurably higher postprandial GLP-1 concentrations compared to controls. While the magnitude of this increase is substantially smaller than what semaglutide achieves, it is consistent and reproducible across studies.
The Supplement Industry's Response
The functional nutrition industry has moved rapidly to capitalize on the GLP-1 connection. NutraIngredients reports that consumer interest in yerba mate for weight management has surged in 2025, driven by awareness of the GLP-1 mechanism and the desire for natural approaches to appetite regulation. Supplement brands are formulating products that combine yerba mate extract with other purported GLP-1 stimulators — berberine, chromium, probiotics — to create 'GLP-1 support' stacks positioned as complements to, or natural alternatives for, pharmaceutical interventions.
This positioning carries both scientific legitimacy and commercial risk. The legitimacy lies in the documented, peer-reviewed evidence that yerba mate does modulate GLP-1 secretion. The risk lies in consumer expectations shaped by the dramatic efficacy of pharmaceutical agonists — expectations that no dietary supplement can responsibly promise to match. Regulatory bodies in the US and EU have begun scrutinizing weight management claims made by supplement brands in the GLP-1 era, and brands that overstate yerba mate's capabilities face enforcement action.
The Novonesis-Novo Nordisk Axis
Adding an institutional dimension to the metabolic health conversation, Novonesis (formerly Chr. Hansen) and Novo Nordisk — the pharmaceutical company behind semaglutide — announced a research collaboration in 2025 to investigate the gut microbiome's role in cardiometabolic health. Their focus on developing synbiotic food biotic solutions to support blood glucose and cholesterol levels signals that even the pharmaceutical industry recognizes the potential for food-derived interventions to complement pharmacological approaches. Yerba mate, with its documented effects on both GLP-1 and the gut microbiome, sits at the intersection of these converging research streams.
A Measured Perspective
The evidence supports characterizing yerba mate as a dietary beverage that naturally modulates metabolic parameters relevant to weight management — including GLP-1 secretion, lipid metabolism, and postprandial glucose response. It does not support characterizing yerba mate as a substitute for pharmaceutical GLP-1 agonists, nor as a 'natural Ozempic.' The distinction is important, both for scientific integrity and for consumer protection. What yerba mate offers is something fundamentally different: a culturally embedded, centuries-tested dietary practice that happens to engage the same hormonal system that pharmaceutical science has identified as central to metabolic regulation. That convergence — between traditional use and molecular pharmacology — is itself a finding worth taking seriously.